StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.52 Million | -8.95 Million | -3.06 Million | -4.59 Million | -3.29 Million | -3.82 Million |
| Net Income | -11.41 Million | -7.48 Million | -6.86 Million | -3.48 Million | -3.94 Million | -2.94 Million |
| Depreciation & Amortization | 437.44 Thousand | 509.27 Thousand | 216.33 Thousand | 298.08 Thousand | 310.8 Thousand | 347.38 Thousand |
| Deferred income taxes | - | -1.64 Million | 2.81 Million | -2.4 Million | -1.54 Million | -1.17 Million |
| Stock-based compensation | 238.5 Thousand | 390.94 Thousand | 636.74 Thousand | 741.45 Thousand | 426.48 Thousand | 392.03 Thousand |
| Change in working capital | 3.7 Million | -460.18 Thousand | -80.47 Thousand | -376.58 Thousand | 339.15 Thousand | 594.94 Thousand |
| Other non-cash items | 3.5 Million | -267.16 Thousand | 209.23 Thousand | 634.21 Thousand | 1.11 Million | -1.03 Million |
| Investing Cash Flow | - | -20.96 Thousand | -72.31 Thousand | -33.37 Thousand | -2794.00 | - |
| Investments in PPE | 2.44 | -148.22 Thousand | -72.31 Thousand | -44.37 Thousand | -2794.00 | - |
| Acquisitions | - | 80.78 Thousand | - | 11.25 Thousand | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 46.48 Thousand | - | -255.00 | - | - |
| Financing Cash Flow | 1.83 Million | 4.1 Million | 9.66 Million | 4.58 Million | 3.35 Million | 3.65 Million |
| Debt repayment | -307.32 Thousand | -404.39 Thousand | -401.41 Thousand | -343.13 Thousand | -110 Thousand | -160 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.54 Million | 3.1 Million | 9.55 Million | 3.94 Million | 1.05 Million | 1.73 Million |
| Other Financing Activities | 597.5 Thousand | 1.4 Million | 512.88 Thousand | 991.69 Thousand | 2.41 Million | 2.07 Million |
| Accounts receivables | 95.65 Thousand | -52.94 Thousand | -55.01 Thousand | 23.94 Thousand | 10.22 Thousand | 32.14 Thousand |
| Accounts payables | 3.26 Million | -323.81 Thousand | -152.05 Thousand | -478.36 Thousand | 262.53 Thousand | 267.97 Thousand |
| Inventory | 313.18 Thousand | -53.8 Thousand | -267.25 Thousand | 23.21 Thousand | -25.3 Thousand | 13.15 Thousand |
| Other working capital | 34.41 Thousand | -29.61 Thousand | 393.85 Thousand | 54.61 Thousand | 364.45 Thousand | 581.78 Thousand |
| Cash at beginning of period | 1.72 Million | 6.59 Million | 71.12 Thousand | 106.22 Thousand | 41.22 Thousand | 213.84 Thousand |
| Cash at end of period | 15.68 Thousand | 1.72 Million | 6.59 Million | 71.12 Thousand | 106.22 Thousand | 41.22 Thousand |
| Capital Expenditure | 2.44 | -148.22 Thousand | -72.31 Thousand | -44.37 Thousand | -2794.00 | - |
| Effect of forex changes on cash | -13.01 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | -1.7 Million | -4.87 Million | 6.52 Million | -35.1 Thousand | 65 Thousand | -172.61 Thousand |
| Free Cash Flow | -3.52 Million | -9.1 Million | -3.13 Million | -4.63 Million | -3.29 Million | -3.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -649.46 Thousand | -384.62 Thousand | -821.88 Thousand | -401.53 Thousand | -1.81 Million | -9.49 Million |
| Depreciation & Amortization | 43.81 Thousand | 18.19 Thousand | 38.09 Thousand | 59.57 Thousand | 59.57 Thousand | 125.75 Thousand |
| Deferred income taxes | - | - | -179 Thousand | -266.21 Thousand | - | - |
| Stock-based compensation | 11.78 Thousand | 11.94 Thousand | 261.09 Thousand | 65.16 Thousand | 65.16 Thousand | 238.5 Thousand |
| Change in working capital | 608.58 Thousand | 209.25 Thousand | 679.17 Thousand | 373.12 Thousand | 946.67 Thousand | 1.14 Million |
| Other non-cash items | -77.63 Thousand | -58.16 Thousand | 70.34 Thousand | 176.95 Thousand | 517.25 Thousand | 7.33 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | -0.06 | 3.24 | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 78.1 Thousand | 71.76 Thousand | -87.93 Thousand | 20.85 Thousand | 243.85 Thousand | 650.59 Thousand |
| Debt repayment | -78.1 Thousand | -71.76 Thousand | -116.67 Thousand | -295.94 Thousand | -67.65 Thousand | -67.65 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 18.51 Thousand | 279.76 Thousand | - | 206 Thousand |
| Other Financing Activities | -31.66 Thousand | 36.77 Thousand | 10.22 Thousand | 37.03 Thousand | 311.5 Thousand | 512.24 Thousand |
| Accounts receivables | -42.55 Thousand | -7631.76 | -6240.00 | 22.05 Thousand | -41.2 Thousand | 11.1 Thousand |
| Accounts payables | 682.36 Thousand | 166.83 Thousand | 510.32 Thousand | 588.27 Thousand | 898.54 Thousand | 953.76 Thousand |
| Inventory | - | - | 60.37 Thousand | -45.40 | 12.67 Thousand | 142.76 Thousand |
| Other working capital | 651.14 Thousand | 50.05 Thousand | 114.71 Thousand | -237.16 Thousand | 76.65 Thousand | 34.05 Thousand |
| Cash at beginning of period | 5536.00 | 23.97 Thousand | 64.2 Thousand | 36.29 Thousand | 15.68 Thousand | 33.25 Thousand |
| Cash at end of period | 20.72 Thousand | 5530.29 | 24.09 Thousand | 64.2 Thousand | 36.29 Thousand | 15.68 Thousand |
| Capital Expenditure | -0.06 | 3.24 | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | -13.01 Thousand |
| Net cash flow / Change in cash | 15.18 Thousand | -18.44 Thousand | -40.11 Thousand | 27.91 Thousand | 20.61 Thousand | -17.56 Thousand |
| Free Cash Flow | -62.92 Thousand | -92.51 Thousand | 47.81 Thousand | 7055.00 | -223.23 Thousand | -655.15 Thousand |
DANE
PSKOF
MNKS
TGIFF
CYAN
2719